Gold bars to be exempt from tariffs, White House clarifies
SAN DIEGO - aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company with a market capitalization of $480 million, announced positive interim results from a Phase 2 study of its lead therapeutic candidate, efzofitimod, for treating systemic sclerosis-related interstitial lung disease (SSc-ILD). The company’s stock has shown remarkable momentum, delivering a 184% return over the past year. According to InvestingPro analysis, the company maintains a healthy financial position with a current ratio of 7.79, indicating strong liquidity to fund its clinical programs. The study showed that three out of four patients with diffuse SSc-ILD experienced clinically significant improvements.
The ongoing EFZO-CONNECT™ study’s interim analysis assessed eight patients, including five with diffuse SSc-ILD and three with limited SSc-ILD. According to the modified Rodnan Skin Score (mRSS), which measures skin fibrosis, all patients had stable or improved scores. While the company is not yet profitable, with an EBITDA of -$66.35 million, InvestingPro data shows that three analysts have recently revised their earnings expectations upward for the upcoming period. Get access to 12 more exclusive ProTips and comprehensive financial analysis through InvestingPro’s detailed research reports. Notably, three out of four patients treated with efzofitimod showed a 4-point or greater improvement, surpassing the minimal clinically important difference at 12 weeks.
In addition to skin assessments, the study also tracked serum biomarkers, observing preliminary signals of improvement for inflammatory and disease biomarkers. aTyr Pharma reported that efzofitimod was generally safe and well tolerated at all doses, with no serious adverse events related to the treatment.
The EFZO-CONNECT™ study is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, safety, and tolerability of efzofitimod in SSc-ILD patients. This 28-week study involves dosing intravenously monthly for a total of six doses, with a primary objective to assess the impact on pulmonary, cutaneous, and systemic manifestations of the disease.
SSc-ILD is a chronic autoimmune disease that can lead to scarring and loss of lung function, and is the leading cause of death in patients with SSc. Current treatments focus on slowing lung function decline but often come with significant toxicity.
Efzofitimod has received U.S. Food and Drug Administration (FDA) and European Union orphan drug designations, as well as U.S. FDA Fast Track designation for SSc.
aTyr Pharma’s approach utilizes tRNA synthetase biology to develop therapies aimed at resolving inflammation and preventing fibrosis progression. The company’s pipeline includes efzofitimod, which is also being investigated in a global Phase 3 study for pulmonary sarcoidosis, another form of ILD.
These findings are based on a press release statement and further updates are expected upon the trial’s completion. The stock is currently trading near its 52-week high of $5.75, reflecting strong investor confidence in the company’s clinical progress. Discover more insights about aTyr Pharma and other biotech opportunities through InvestingPro’s exclusive research reports, covering over 1,400 US stocks with detailed analysis and actionable intelligence.
In other recent news, aTyr Pharma has made significant advancements with its investigational drug candidate, ATYR0101, which has shown promise in preclinical models for treating fibrosis. The company plans to present details on this candidate at the upcoming American Thoracic Society 2025 Respiratory Innovation Summit. Meanwhile, Cantor Fitzgerald has reiterated its Overweight rating on aTyr Pharma, highlighting the upcoming Phase 3 trial results for efzofitimod, a drug aimed at treating pulmonary sarcoidosis, expected in the third quarter of 2025. This rating reflects optimism over recent updates to the trial’s statistical analysis, which could enhance its success chances.
Additionally, aTyr Pharma has appointed Dalia R. Rayes as the new Head of Commercial for its efzofitimod program, focusing on commercial strategy and operations. Rayes’ experience in launching rare disease products is expected to be pivotal as the company anticipates the Phase 3 trial results. In financial developments, H.C. Wainwright maintained a Buy rating with a $35 price target for aTyr Pharma following the company’s fourth-quarter and full-year 2024 financial results, which surpassed estimates. The company ended the year with $75.1 million in cash reserves and raised $18.1 million from its ATM offering facility in early 2025. These financial moves aim to support aTyr Pharma through upcoming milestones, including the anticipated EFZO-FIT trial readout.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.